| Literature DB >> 33923659 |
Chien-Tung Chiu1, Chung-Hsu Lai2,3, Yi-Han Huang3, Chih-Hui Yang4, Jiun-Nong Lin1,2,3.
Abstract
Elizabethkingia anophelis has recently emerged as a cause of life-threatening infections. This study compared the results of antimicrobial susceptibility testing (AST) conducted for E. anophelis through different methods. E. anophelis isolates collected between January 2005 and June 2019 were examined for their susceptibility to 14 antimicrobial agents by using disk diffusion, gradient diffusion (Etest; bioMérieux S.A., Marcy l'Etoile, France), and agar dilution methods. The agar dilution method was the reference assay. According to the agar dilution method, the isolates exhibited the highest susceptibility to minocycline (100%), doxycycline (97.6%), rifampin (95.2%), and levofloxacin (78.6%). A very major error rate of >1.5% was observed for nine antibiotics tested using the disk diffusion method. The overall categorical agreement rate between the disk diffusion and agar dilution methods was 74.8%, and ceftazidime, minocycline, levofloxacin, and rifampin met the minimum requirements for discrepancy and agreement rates. The Etest method tended to produce lower log2 minimum inhibitory concentrations for the antibiotics, except for trimethoprim-sulfamethoxazole and rifampin; the method resulted in very major errors for nine antibiotics. The overall essential and categorical agreement rates between the Etest and agar dilution methods were 67.3% and 76.1%, respectively. The Etest method demonstrated acceptable discrepancy and agreement rates for ceftazidime, minocycline, doxycycline, levofloxacin, and rifampin. AST results obtained through the disk diffusion and Etest methods for multiple antibiotics differed significantly from those obtained using the agar dilution method. These two assays should not be a routine alternative for AST for E. anophelis.Entities:
Keywords: Elizabethkingia anophelis; agar dilution; antimicrobial susceptibility testing; disk diffusion; gradient diffusion
Year: 2021 PMID: 33923659 PMCID: PMC8073607 DOI: 10.3390/antibiotics10040450
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
The ranges of antimicrobial concentrations used in this study.
| Antimicrobial Agent a | Susceptibility Testing Assay | ||
|---|---|---|---|
| Agar Dilution (mg/L) | Disk Diffusion (µg) | Etest (mg/L) | |
| Piperacillin | 2–256 | 100 | 0.016–256 |
| Piperacillin–tazobactam | 2/4–256/4 | 100/10 | 0.016/4–256/4 |
| Ceftazidime | 8–256 | 30 | 0.016–256 |
| Cefepime | 1–128 | 30 | 0.016–256 |
| Gentamicin | 1–128 | 10 | 0.016–256 |
| Amikacin | 2–256 | 30 | 0.016–256 |
| Minocycline | 0.0625–2 | 30 | 0.016–256 |
| Doxycycline | 0.25–16 | 30 | 0.016–256 |
| Tigecycline | 0.25–32 | 15 | 0.016–256 |
| Ciprofloxacin | 0.25–32 | 5 | 0.002–32 |
| Levofloxacin | 0.25–32 | 5 | 0.002–32 |
| Trimethoprim–sulfamethoxazole | 0.5/9.5–32/608 | 1.25/23.75 | 0.002/0.38 – 32/608 |
| Rifampin | 0.25–16 | 5 | 0.016–256 |
| Vancomycin | 2–256 | 30 | 0.016–256 |
a Sources of standard powders: ciprofloxacin and levofloxacin were obtained from Sigma-Aldrich (St. Louis, MO, USA), and others were bought from Cyrusbioscience (Taipei, Taiwan).
Antimicrobial MICs (mg/L) and susceptible rates of 84 E. anophelis isolates determined using the agar dilution, Etest, and disk diffusion methods.
| Antimicrobial Agent | Agar Dilution | Disk Diffusion | Etest | ||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC Range | MIC50 | MIC90 | % Sa | % Sa | MIC Range | MIC50 | MIC90 | % Sa | |
| Piperacillin | 128–>256 | >256 | >256 | 0 | 4.8 | 8–>256 | >256 | >256 | 2.4 |
| Piperacillin–tazobactam | 256/4–>256/4 | >256/4 | >256/4 | 0 | 22.6 | 8/4–>256/4 | >256/4 | >256/4 | 4.8 |
| Ceftazidime | 256–>256 | >256 | >256 | 0 | 0 | 48–>256 | >256 | >256 | 0 |
| Cefepime | 32–>128 | >128 | >128 | 0 | 21.4 | 1.5–>256 | >256 | >256 | 2.4 |
| Gentamicin | 8–>128 | >128 | >128 | 0 | 9.5 | 3–>256 | 64 | >256 | 13.1 |
| Amikacin | 32–>256 | >256 | >256 | 0 | 6 | 12–>256 | >256 | >256 | 3.6 |
| Minocycline | 0.125–1 | 0.25 | 0.25 | 100 | 100 | 0.023–0.38 | 0.125 | 0.19 | 100 |
| Doxycycline | 1–16 | 2 | 4 | 97.6 | 98.8 | 0.5–16 | 1 | 2 | 97.6 |
| Tigecycline | 2–32 | 8 | 16 | 4.8 | 56 | 0.125–8 | 1.5 | 3 | 77.4 |
| Ciprofloxacin | 1–>32 | 2 | >32 | 8.3 | 51.2 | 0.038–>32 | 0.5 | >32 | 75 |
| Levofloxacin | 0.5–>32 | 2 | 32 | 78.6 | 79.8 | 0.038–>32 | 0.38 | >32 | 79.8 |
| Trimethoprim–sulfamethoxazole | 2/38–32/608 | 8/152 | 16/304 | 1.2 | 1.2 | 0.38/7.22–>32/608 | >32/608 | >32/608 | 4.8 |
| Rifampin | <0.25–>16 | 0.5 | 1 | 95.2 | 85.7 | 0.125–>32 | 0.38 | 0.75 | 94 |
| Vancomycin | 8–256 | 32 | 64 | 0 | 25 | 3 –3 2 | 8 | 16 | 9.5 |
a S, susceptible.
Comparison of the disk diffusion and Etest methods with the agar dilution method for antimicrobial susceptibility testing of 84 E. anophelis isolates.
| Antimicrobial Agent | Technique | Isolate no. of MIC log2 Dilutions Differ from the Agar Dilution | Essential Agreement (%) | Interpretive Errors (%) | Categorical Agreement (%) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤−3 | −2 | −1 | 0 | +1 | +2 | ≥+3 | Very Major | Major | Minor | ||||
| Piperacillin | Disk diffusion | – | – | – | – | – | – | – | – | 4.8 | N/A | 13.1 | 82.1 |
| Etest | 4 | 1 | 1 | 55 | 21 | 2 | 0 | 91.7 | 2.4 | N/A | 2.4 | 95.2 | |
| Piperacillin–tazobactam | Disk diffusion | – | – | – | – | – | – | – | – | 22.6 | N/A | 45.2 | 32.1 |
| Etest | 7 | 5 | 3 | 48 | 20 | 1 | 0 | 84.5 | 4.8 | N/A | 11.9 | 83.3 | |
| Ceftazidime | Disk diffusion | – | – | – | – | – | – | – | – | 0 | N/A | 0 | 100 |
| Etest | 3 | 0 | 1 | 77 | 3 | 0 | 0 | 96.4 | 0 | N/A | 0 | 100 | |
| Cefepime | Disk diffusion | – | – | – | – | – | – | – | – | 21.4 | N/A | 8.3 | 70.2 |
| Etest | 19 | 4 | 3 | 58 | 0 | 0 | 0 | 72.6 | 2.4 | N/A | 16.7 | 81 | |
| Gentamicin | Disk diffusion | – | – | – | – | – | – | – | – | 9.6 | N/A | 4.8 | 85.7 |
| Etest | 17 | 21 | 19 | 25 | 2 | 0 | 0 | 54.8 | 13.3 | N/A | 3.6 | 83.3 | |
| Amikacin | Disk diffusion | – | – | – | – | – | – | – | – | 4.8 | N/A | 4.8 | 90.5 |
| Etest | 3 | 8 | 9 | 45 | 16 | 3 | 0 | 83.3 | 3.6 | N/A | 13.1 | 83.3 | |
| Minocycline | Disk diffusion | – | – | – | – | – | – | – | – | 0 | 0 | 0 | 100 |
| Etest | 2 | 13 | 42 | 24 | 3 | 0 | 0 | 82.1 | 0 | 0 | 0 | 100 | |
| Doxycycline | Disk diffusion | – | – | – | – | – | – | – | – | 100 | 0 | 1.2 | 96.4 |
| Etest | 0 | 2 | 32 | 43 | 7 | 0 | 0 | 97.6 | 0 | 0 | 1.2 | 98.8 | |
| Tigecycline | Disk diffusion | – | – | – | – | – | – | – | – | 50.9 | 0 | 48 | 19 |
| Etest | 25 | 25 | 29 | 5 | 0 | 0 | 0 | 40.5 | 71.7 | 0 | 44 | 10.7 | |
| Ciprofloxacin | Disk diffusion | – | – | – | – | – | – | – | – | 15.2 | 0 | 52.4 | 41.7 |
| Etest | 18 | 30 | 16 | 19 | 1 | 0 | 0 | 42.9 | 39.4 | 0 | 53.6 | 31 | |
| Levofloxacin | Disk diffusion | – | – | – | – | – | – | – | – | 0 | 0 | 1.2 | 98.8 |
| Etest | 13 | 20 | 26 | 9 | 6 | 0 | 0 | 48.8 | 0 | 0 | 1.2 | 98.8 | |
| Trimethoprim–sulfamethoxazole | Disk diffusion | – | – | – | – | – | – | – | – | 1.2 | 100 | 2.4 | 95.2 |
| Etest | 3 | 2 | 6 | 8 | 4 | 22 | 39 | 21.4 | 4.8 | 100 | 0 | 94 | |
| Rifampin | Disk diffusion | – | – | – | – | – | – | – | – | 0 | 0 | 9.5 | 90.5 |
| Etest | 0 | 0 | 14 | 38 | 19 | 13 | 0 | 84.5 | 0 | 0 | 1.2 | 98.8 | |
| Vancomycin | Disk diffusion | – | – | – | – | – | – | – | – | 25.3 | NA | 32.1 | 45.2 |
| Etest | 8 | 41 | 33 | 2 | 0 | 0 | 0 | 41.7 | 5.3 | NA | 88.1 | 7.1 | |
Figure 1Categorical agreement between the disk diffusion and agar dilution methods for the antimicrobial susceptibility testing of E. anophelis. The broken line indicates an agreement rate of 90%.
Figure 2Essential agreement and categorical agreement between the Etest and agar dilution methods for the antimicrobial susceptibility testing of E. anophelis. The broken line indicates an agreement rate of 90%.